Pharmacelsus is a research-driven CRO (Contract Research Organisation) providing 15 years of high quality preclinical services to life science companies and academic institutions. Pharmacelsus’ service portfolio covers drug discovery and development process, in vitro, in vivo, ex vivo and bioanalytical studies. The company has been GLP-certified since 2008.
Our portfolio encompasses:
For several years, Pharmacelsus successfully participates in funded research projects covering different research programs (EU FP6 and FP7, Horizon 2020, BMWi, BMBF, Eurostars, etc.).
Within ZIM Cooperation network Nanopharm, we offer our entire portfolio, particularly in vivo studies for the determination of bioavailability and/ or bioequivalence, in vitro nanotoxicological studies and quantification of small molecules and phytopharmaceuticals via LC-MS.